Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies

Elucidating the mechanisms of action of parecoxib in the MG-63 osteosarcoma cell line

(2020) Sílvia Lemos et al.   ANTI-CANCER DRUGS

Ribonucleotide reductase inhibitors suppress SAMHD 1 ara‐ CTP ase activity enhancing cytarabine efficacy

(2020) Sean G Rudd et al.   EMBO Molecular Medicine

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

(2020) Antoine Italiano et al.   LANCET ONCOLOGY

Immuno-genomic landscape of osteosarcoma

(2020) Chia-Chin Wu et al.   Nature Communications

Relapse fated latent diagnosis subclones in acute B lineage leukaemia are drug tolerant and possess distinct metabolic programs

(2020) Stephanie M. Dobson et al.   Cancer Discovery

Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients

(2020) Vissia Viglietta et al.   INVESTIGATIONAL NEW DRUGS

Afatinib is active in osteosarcoma in osteosarcoma cell lines

(2020) Marlid Cruz-Ramos et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments

(2020) Marilù Fanelli et al.   Frontiers in Oncology

Circular RNA hsa_circ_0000073 contributes to osteosarcoma cell proliferation, migration, invasion and methotrexate resistance by sponging miR-145-5p and miR-151-3p and upregulating NRAS

(2020) Xia Li et al.   Aging-US

Author Correction: Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma

(2020) Dan Liao et al.   NATURE CELL BIOLOGY

Bisphosphonates in common pediatric and adult bone sarcomas

(2020) Marie-Francoise Heymann et al.   BONE

Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2β

(2020) Nikolas Herold   Expert Opinion on Drug Discovery

Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1

(2019) Yantao Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The role and mechanisms of action of microRNAs in cancer drug resistance

(2019) Wengong Si et al.   Clinical Epigenetics

Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma

(2019) Suchismita Mohanty et al.   Cell Death & Disease

Drug resistance‐related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies

(2019) Ruiling Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

SKA1 induces de novo MTX-resistance in osteosarcoma through inhibiting FPGS transcription

(2019) Wenxi Yu et al.   FEBS Journal

Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment

(2019) Claudia Maria Hattinger et al.   Expert Opinion on Drug Metabolism & Toxicology

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

(2019) Sigbjørn Smeland et al.   EUROPEAN JOURNAL OF CANCER

A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup

(2019) Carlo Lancia et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients

(2019) Krithika Bhuvaneshwar et al.   BMC CANCER

Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study

(2019) Sophie Piperno‐Neumann et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

(2019) Lara E. Davis et al.   JOURNAL OF CLINICAL ONCOLOGY

Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma

(2019) Carlo Lancia et al.   BMJ Open

Ontogeny of Tumor-Associated Macrophages

(2019) Marie Laviron et al.   Frontiers in Immunology

In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice

(2019) Maria Eugénia Marques da Costa et al.   Cancers

An update on emerging drugs in osteosarcoma: towards tailored therapies?

(2019) Claudia Maria Hattinger et al.   EXPERT OPINION ON EMERGING DRUGS

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

(2019) Melina Arnold et al.   LANCET ONCOLOGY

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

(2019) Gianni Bisogno et al.   LANCET ONCOLOGY

Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don't eat me’ signals off and ‘eat me’ signals on

(2019) Suchismita Mohanty et al.   Molecular Oncology

Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study

(2019) Ji-Man Kang et al.   ONCOLOGY

MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression

(2019) Wei Liang et al.   OncoTargets and Therapy

Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma

(2019) Hongzeng Wu et al.   Journal of Orthopaedic Surgery and Research

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

(2019) Arsen Osipov et al.   Journal for ImmunoTherapy of Cancer

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group

(2019) Lisa M. Kopp et al.   EUROPEAN JOURNAL OF CANCER

Methotrexate–Etoposide–Ifosfamide Compared with Doxorubicin–Cisplatin–Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18–25 Years

(2019) Perrine Marec-Berard et al.   Journal of Adolescent and Young Adult Oncology

Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas

(2019) Naofumi Asano et al.   Scientific Reports

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

(2018) Hadeel Obiedat et al.   BMC Medical Genetics

Molecular targeted therapy: treating cancer with specificity

(2018) Yeuan Ting Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells

(2018) Lu Ding et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

(2018) Hye Jeong Park et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss

(2018) Penelope R. Brock et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

(2018) Natalie J. Neubert et al.   Science Translational Medicine

Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma

(2018) K. Patatsos et al.   Veterinary and Comparative Oncology

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

(2018) Harriett Holme et al.   Scientific Reports

Kinases and Cancer

(2018) Jonas Cicenas et al.   Cancers

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment

(2018) Franck Verrecchia et al.   Frontiers in Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma

(2018) Xin Xiao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: An in vivo study using a murine model of osteosarcoma

(2018) Takahiro Shimizu et al.   JOURNAL OF PEDIATRIC SURGERY

Profiling targetable immune checkpoints in osteosarcoma

(2018) Troy A McEachron et al.   OncoImmunology

Sorafenib: key lessons from over 10 years of experience

(2018) Bernard Escudier et al.   Expert Review of Anticancer Therapy

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

(2018) Florence Duffaud et al.   LANCET ONCOLOGY

Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort

(2018) Todd M Gibson et al.   LANCET ONCOLOGY

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group

(2018) Michael S. Isakoff et al.   PEDIATRIC BLOOD & CANCER

The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases

(2018) Benjamin Navet et al.   Cancers

The development of PARP as a successful target for cancer therapy

(2017) Roberto Ferrara et al.   Expert Review of Anticancer Therapy

Current and future therapeutic approaches for osteosarcoma

(2017) Douglas J. Harrison et al.   Expert Review of Anticancer Therapy

Novel insights and therapeutic interventions for pediatric osteosarcoma

(2017) Leo Kager et al.   Future Oncology

Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention

(2017) Peter A Henriksen   HEART

Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling

(2017) Yandong Lu et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study

(2017) Anthony J. Swerdlow et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial

(2017) Stine Nygaard Nielsen et al.   LANCET ONCOLOGY

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

(2017) Hussein A Tawbi et al.   LANCET ONCOLOGY

Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma

(2017) Q Wang et al.   LEUKEMIA

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer

(2017) April A.N. Rose et al.   PHARMACOLOGY & THERAPEUTICS

Macrophages and skeletal health

(2017) Megan N. Michalski et al.   PHARMACOLOGY & THERAPEUTICS

TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma

(2017) Yanling Tao et al.   Oncology Letters

Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein

(2017) Dapeng Wu et al.   Oncotarget

Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis

(2017) Xueyong Liu et al.   Oncotarget

SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling

(2017) Jun Sheng et al.   Oncotarget

The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia

(2017) Benjamin L. Lampson et al.   Current Hematologic Malignancy Reports

All-Trans Retinoic Acid Prevents Osteosarcoma Metastasis by Inhibiting M2 Polarization of Tumor-Associated Macrophages

(2017) Qian Zhou et al.   Cancer Immunology Research

Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin

(2017) Armin Wiegering et al.   NEOPLASIA

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial

(2017) Anne Gomez-Brouchet et al.   OncoImmunology

The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma

(2017) Marie-Françoise Heymann et al.   CELLULAR IMMUNOLOGY

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives

(2016) Erlinda M. Gordon et al.   ADVANCES IN THERAPY

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone

(2016) E. Palmerini et al.   BMC CANCER

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade

(2016) Zhaolin Chen et al.   CANCER LETTERS

Glutathione-Associated Enzymes In Anticancer Drug Resistance

(2016) K. D. Tew   CANCER RESEARCH

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma

(2016) Y. Mao et al.   CLINICAL CANCER RESEARCH

Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma

(2016) Marilù Fanelli et al.   CURRENT CANCER DRUG TARGETS

Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors

(2016) Doriana Fruci et al.   CURRENT DRUG METABOLISM

CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma

(2016) Qinglin Han et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

(2016) Joanne P. Lagmay et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray

(2016) Yan Gao et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial

(2016) Sophie Piperno-Neumann et al.   LANCET ONCOLOGY

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

(2016) Neyssa M Marina et al.   LANCET ONCOLOGY

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Nitidine chloride suppresses epithelial-to-mesenchymal transition in osteosarcoma cell migration and invasion through Akt/GSK-3β/Snail signaling pathway

(2016) Zhenxiu Cheng et al.   ONCOLOGY REPORTS

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

(2016) Peter M. Anderson et al.   PEDIATRIC BLOOD & CANCER

Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients

(2016) Claudia M Hattinger et al.   PHARMACOGENOMICS

Glucocorticoids and chronic inflammation

(2016) Rainer H. Straub et al.   RHEUMATOLOGY

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance

(2016) Tang Liu et al.   Oncotarget

Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma

(2016) Clotilde Dumars et al.   Oncotarget

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

(2016) Florian Engert et al.   Oncotarget

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma

(2016) Valerie B. Sampson et al.   Oncotarget

miR-513a-5p regulates radiosensitivity of osteosarcoma by targeting human apurinic/apyrimidinic endonuclease

(2016) Nan Dai et al.   Oncotarget

Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance

(2016) Sofia Avnet et al.   Oncotarget

Prognostic value of inflammation-based scores in patients with osteosarcoma

(2016) Bangjian Liu et al.   Scientific Reports

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

(2016) Pratistha Koirala et al.   Scientific Reports

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

(2015) A. Gupte et al.   CLINICAL CANCER RESEARCH

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

(2015) M. S. Merchant et al.   CLINICAL CANCER RESEARCH

An update on chemotherapy for osteosarcoma

(2015) Stefano Ferrari et al.   EXPERT OPINION ON PHARMACOTHERAPY

Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy

(2015) Claudia Maria Hattinger et al.   HISTOPATHOLOGY

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

(2015) Stefan S. Bielack et al.   JOURNAL OF CLINICAL ONCOLOGY

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

(2015) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

(2015) Michael S. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance

(2015) Florian Sevelda et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Germline TP53 Variants and Susceptibility to Osteosarcoma

(2015) Lisa Mirabello et al.   JNCI-Journal of the National Cancer Institute

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

(2015) Giovanni Grignani et al.   LANCET ONCOLOGY

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

(2015) Jean-Charles Soria et al.   LANCET ONCOLOGY

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis

(2015) Branden S Moriarity et al.   NATURE GENETICS

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program

(2015) C. Patrick Reynolds et al.   PEDIATRIC BLOOD & CANCER

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

(2015) Michael Roth et al.   PEDIATRIC BLOOD & CANCER

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

(2015) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER

Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

(2015) Cindy L. Schwartz et al.   PEDIATRIC BLOOD & CANCER

TRIM37 promoted the growth and migration of the pancreatic cancer cells

(2015) Jianxin Jiang et al.   TUMOR BIOLOGY

Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal

(2015) Suoyuan Li et al.   TUMOR BIOLOGY

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

(2015) Michal Kovac et al.   Nature Communications

Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells

(2015) Upal Basu-Roy et al.   Nature Communications

ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib

(2015) Jiani Liu et al.   Oncotarget

CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models

(2015) Ji-Feng Xu et al.   Oncotarget

Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines

(2015) Xiao-rong Yang et al.   Journal of Orthopaedic Surgery and Research

Germline TP53 Variants and Susceptibility to Osteosarcoma

(2015) Lisa Mirabello et al.   JNCI-Journal of the National Cancer Institute

CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study

(2015) Benedikt Fritzsching et al.   OncoImmunology

Combination Immunotherapy for Melanoma

(2015) Howard L. Kaufman   JAMA Oncology

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment†

(2014) J. S. Whelan et al.   ANNALS OF ONCOLOGY

Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization

(2014) Pierre Kunz et al.   ANNALS OF SURGICAL ONCOLOGY

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms

(2014) Shiwei Deng et al.   BMC CANCER

Pleiotropic effects of bisphosphonates on osteosarcoma

(2014) Tetsuro Ohba et al.   BONE

Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?

(2014) Anthony J. Mutsaers et al.   BONE

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925

(2014) X Yang et al.   BRITISH JOURNAL OF CANCER

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

(2014) Alberto S. Pappo et al.   CANCER

Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma

(2014) A. Lamora et al.   CLINICAL CANCER RESEARCH

Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy

(2014) M. Xu et al.   Current Oncology

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment

(2014) Aude I. Ségaliny et al.   INTERNATIONAL JOURNAL OF CANCER

Evaluation of outcome and prognostic factors for dogs living greater than one year after diagnosis of osteosarcoma: 90 cases (1997–2008)

(2014) William T. N. Culp et al.   JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

Association between P-Glycoprotein expression and response to chemotherapy in patients with osteosarcoma: A systematic and meta-analysis

(2014) Wu-Sheng Kan et al.   Journal of Cancer Research and Therapeutics

Sex- and Age-Related Chemotherapy Toxicity in Patients with Non-Metastatic Osteosarcoma

(2014) S. Ferrari et al.   JOURNAL OF CHEMOTHERAPY

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program

(2014) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

(2014) Jennifer A. Perry et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

APEX1 Gene Amplification and Its Protein Overexpression in Osteosarcoma: Correlation with Recurrence, Metastasis, and Survival

(2014) Jilong Yang et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy

(2014) Chaoqun Yang et al.   TUMOR BIOLOGY

Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy

(2014) Shizhang Liu et al.   TUMOR BIOLOGY

Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies

(2014) Yu Liu et al.   TUMOR BIOLOGY

Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma

(2014) Xin Xiao et al.   TUMOR BIOLOGY

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

Estrogen-Related Receptor Alpha Confers Methotrexate Resistance via Attenuation of Reactive Oxygen Species Production and P53 Mediated Apoptosis in Osteosarcoma Cells

(2014) Peng Chen et al.   Biomed Research International

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression

(2014) Damya Laoui et al.   Frontiers in Immunology

Glutathione S-transferase P1 and DNA Polymorphisms with the Response to Chemotherapy and the Prognosis of Bone Tumor

(2013) Li-Min Yang et al.   Asian Pacific Journal of Cancer Prevention

Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma

(2013) Winnie W. Lo et al.   CANCER

Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression

(2013) Chia-Hsin Chan et al.   CELL

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models

(2013) Y. Pignochino et al.   CLINICAL CANCER RESEARCH

Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor

(2013) Marieke L. Kuijjer et al.   INTERNATIONAL JOURNAL OF CANCER

Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic

(2013) Yu Cai et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Major Efficacy of Trabectedin in 2 Metastatic Osteosarcoma Patients with Wild-Type Asp1104 ERCC5 Tumor Status

(2013) Lauris Gastaud et al.   ONKOLOGIE

Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: A longitudinal study

(2013) Tanya Renae Brown et al.   PEDIATRIC BLOOD & CANCER

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

(2013) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments

(2013) P.M. Anderson et al.   PEDIATRIC BLOOD & CANCER

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Efficacy of Glucarpidase (Carboxypeptidase G2) in Patients with Acute Kidney Injury After High-Dose Methotrexate Therapy

(2013) Brigitte C. Widemann et al.   PHARMACOTHERAPY

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Nucleotide Excision Repair in Eukaryotes

(2013) O. D. Scharer   Cold Spring Harbor Perspectives in Biology

Mechanisms and insights into drug resistance in cancer

(2013) Hiba Zahreddine et al.   Frontiers in Pharmacology

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse

(2013) Aurelia Nguyen et al.   Cancers

Notch Signaling is Associated with ALDH Activity and an Aggressive Metastatic Phenotype in Murine Osteosarcoma Cells

(2013) Xiaodong Mu et al.   Frontiers in Oncology

Eribulin: A Novel Cytotoxic Chemotherapy Agent

(2012) Jessica N Preston et al.   ANNALS OF PHARMACOTHERAPY

Predictive Potential of Glutathione S-Transferase Polymorphisms for Prognosis of Osteosarcoma Patients on Chemotherapy

(2012) Shai-Lin Zhang et al.   Asian Pacific Journal of Cancer Prevention

Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma

(2012) Jun Huang et al.   Autophagy

The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis

(2012) Liliana Endo-Munoz et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line

(2012) Sara R Martins-Neves et al.   BMC CANCER

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Current Status of Methods to Assess Cancer Drug Resistance

(2012) Theodor H. Lippert et al.   International Journal of Medical Sciences

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

(2012) David Ebb et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1

(2012) Stefano Ferrari et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting hedgehog-GLI-2 pathway in osteosarcoma

(2012) Wen Yang et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring Cancer

(2012) Michelle R. Goulart et al.   PLoS One

Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?

(2012) Jun Ah Lee et al.   Cancer Research and Treatment

Cancer stem cells in osteosarcoma: Recent progress and perspective

(2011) Bin Liu et al.   ACTA ONCOLOGICA

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

(2011) G. Grignani et al.   ANNALS OF ONCOLOGY

Cell surface receptor expression patterns in osteosarcoma

(2011) Sheref E. Hassan et al.   CANCER

Frontline treatment of localized osteosarcoma without methotrexate

(2011) Najat C. Daw et al.   CANCER

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma

(2011) Rachael E. Windsor et al.   CANCER

High-Frequency Canonical Wnt Activation in Multiple Sarcoma Subtypes Drives Proliferation through a TCF/β-Catenin Target Gene, CDC25A

(2011) Sapna Vijayakumar et al.   CANCER CELL

Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients

(2011) Xing Wu et al.   Cancer Epidemiology

IGF1R-Targeted Therapy and Its Enhancement of Doxorubicin Chemosensitivity in Human Osteosarcoma Cell Lines

(2011) Frederick Luk et al.   CANCER INVESTIGATION

Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response

(2011) J. Fucikova et al.   CANCER RESEARCH

HMGB1 Promotes Drug Resistance in Osteosarcoma

(2011) J. Huang et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

(2011) E. P. Buddingh et al.   CLINICAL CANCER RESEARCH

Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial

(2011) H. Assi et al.   Current Oncology

Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?

(2011) Jakob K. Anninga et al.   EUROPEAN JOURNAL OF CANCER

Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models

(2011) Julie Rousseau et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma

(2011) Yin-He Wang et al.   JOURNAL OF SURGICAL ONCOLOGY

PARP and Cancer — If It's Broke, Don't Fix It

(2011) Lisa A. Carey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas

(2011) U Basu-Roy et al.   ONCOGENE

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling

(2011) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours

(2011) C. London et al.   Veterinary and Comparative Oncology

Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma

(2010) Claudia Blattmann et al.   BMC CANCER

Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases

(2010) L. Endo-Munoz et al.   CANCER RESEARCH

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group

(2010) C. A. S. Arndt et al.   CLINICAL CANCER RESEARCH

Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis

(2010) Marc Baud'Huin et al.   JOURNAL OF PATHOLOGY

Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma

(2010) B.J. Biller et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects

(2010) Katherine A Janeway et al.   LANCET ONCOLOGY

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells

(2010) Bo Song et al.   Molecular Cancer

HMGB1 release and redox regulates autophagy and apoptosis in cancer cells

(2010) D Tang et al.   ONCOGENE

Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance

(2010) Honoki   ONCOLOGY REPORTS

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

(2010) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Review of mifamurtide in the treatment of patients with osteosarcoma

(2010) Leo Kager et al.   Therapeutics and Clinical Risk Management

Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line

(2009) Thangarajan Rajkumar et al.   ANTI-CANCER DRUGS

Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing

(2009) Yao Zhao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients

(2009) Berger Massimo et al.   CANCER

Osteosarcoma incidence and survival rates from 1973 to 2004

(2009) Lisa Mirabello et al.   CANCER

Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses

(2009) Joseph L. Sottnik et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma

(2009) Paul A Meyers   Expert Review of Anticancer Therapy

Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines

(2009) Honoki   INTERNATIONAL JOURNAL OF ONCOLOGY

Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment

(2009) Riccardo Di Fiore et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children

(2009) Odile Oberlin et al.   JOURNAL OF CLINICAL ONCOLOGY

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

(2009) Yoshiaki Kubota et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Methotrexate in Pediatric Osteosarcoma: Response and Toxicity in Relation to Genetic Polymorphisms and Dihydrofolate Reductase and Reduced Folate Carrier 1 Expression

(2009) Ana Patiño-García et al.   JOURNAL OF PEDIATRICS

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

(2009) Ymera Pignochino et al.   Molecular Cancer

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

(2009) E. A. Perez   MOLECULAR CANCER THERAPEUTICS

Paget disease: when to treat and when not to treat

(2009) Frederick R. Singer   Nature Reviews Rheumatology

Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells

(2009) B Song et al.   ONCOGENE

The role of interferons in the treatment of osteosarcoma

(2009) Jeremy Whelan et al.   PEDIATRIC BLOOD & CANCER

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

(2009) D Caronia et al.   PHARMACOGENOMICS JOURNAL

VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma

(2009) Quan Zhou et al.   SURGICAL ONCOLOGY-OXFORD

The Nuclear Factor NF- B Pathway in Inflammation

(2009) T. Lawrence   Cold Spring Harbor Perspectives in Biology

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Overcoming Glutathione S-Transferase P1-Related Cisplatin Resistance in Osteosarcoma

(2008) M. Pasello et al.   CANCER RESEARCH

Sodium Thiosulfate Administered Six Hours after Cisplatin Does Not Compromise Antineuroblastoma Activity

(2008) T. M. Harned et al.   CLINICAL CANCER RESEARCH

Polymorphisms and Methylation of the Reduced Folate Carrier in Osteosarcoma

(2008) Rui Yang et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Osteoimmunology: Interactions of the Bone and Immune System

(2008) Joseph Lorenzo et al.   ENDOCRINE REVIEWS

Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines

(2008) Claudia M. Hattinger et al.   GENES CHROMOSOMES & CANCER

Mutations in p53, p53 protein overexpression and breast cancer survival

(2008) Pavel Rossner Jr et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Complexities in Interpretation of Osteosarcoma Clinical Trial Results

(2008) Sally Hunsberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

(2008) Paul A. Meyers et al.   JOURNAL OF CLINICAL ONCOLOGY

Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis

(2008) R A Eliseev et al.   ONCOGENE

Ototoxicity in children treated for osteosarcoma

(2008) Matthew J. Lewis et al.   PEDIATRIC BLOOD & CANCER

Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma

(2007) Maria-Kyriaki A. Kaseta et al.   JOURNAL OF SURGICAL ONCOLOGY

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

(2007) John M. Maris et al.   PEDIATRIC BLOOD & CANCER